Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 14 de 14
1.
Article En | MEDLINE | ID: mdl-34770107

Myasthenia Gravis (MG) is a chronic, life-lasting condition that requires high coordination among different professionals and disciplines. The diagnosis of MG is often delayed and sometimes misdiagnosed. The goal of the care pathway (CP) is to add value to healthcare reducing unnecessary variations. The quality of the care received by patients affected with MG could benefit from the use of CP. We conducted a study aimed to define an inclusive, comprehensive, and multidisciplinary CP for the diagnosis, treatment, and care of MG. The development of the model CP, key interventions, and process indicators is based on the literature review and 85 international MG experts were involved in their evaluation, expressing a judgment of relevance through the Delphi study. 60 activities are included in the model CP and evaluated by the MG experts were valid and feasible. The 60 activities were then translated into 14 key interventions and 24 process indicators. We believe that the developed model CP will help for MG patients to have a timely diagnosis and high-quality, accessible, and cost-effective treatments and care. We also believe that the development of model CPs for other rare diseases is feasible and could aid in the integration of evidence-based knowledge into clinical practice.


Myasthenia Gravis , Humans , Myasthenia Gravis/diagnosis , Myasthenia Gravis/therapy
2.
Clin Neuroradiol ; 30(3): 553-558, 2020 Sep.
Article En | MEDLINE | ID: mdl-31143968

BACKGROUND: Multiple sclerosis (MS) patients represent a population potentially affected by the intracerebral accumulation of gadolinium-based contrast agents (GBCA) due to repeated magnetic resonance imaging (MRI) performed during their lifetime; however, MRI is still the best tool to monitor MS inflammatory activity. OBJECTIVE: This study aimed to evaluate the relevance of GBCA injections during the MRI follow-up of MS patients under natalizumab (Tysabri) treatment. METHODS: The MRI data results were retrospectively reviewed in a monocentric study (University Hospital of Toulouse, France) from all consecutive patients treated with natalizumab from January 2014 to January 2017. For each examination during the whole MRI follow-up, new lesions (enhancing and non-enhancing) were analyzed. RESULTS: A total of 129 patients were included in this study (65% female, mean age = 41 years, mean treatment duration 6.5 years, 50% positive for John Cunningham virus) and benefited from 735 MRIs with GBCA. Only 3 MRIs showed a new enhancing lesion, systematically encountered after treatment discontinuation. CONCLUSION: According to this study based on the clinical and radiological practice, the systematic use of GBCA seems of limited relevance in the MRI follow-up of asymptomatic patients treated continuously with natalizumab.


Contrast Media/administration & dosage , Gadolinium/administration & dosage , Immunologic Factors/therapeutic use , Magnetic Resonance Imaging , Multiple Sclerosis/diagnostic imaging , Multiple Sclerosis/drug therapy , Natalizumab/therapeutic use , Adult , Female , France , Humans , Male , Middle Aged , Retrospective Studies
3.
J Neuroradiol ; 46(5): 312-318, 2019 Sep.
Article En | MEDLINE | ID: mdl-31228536

The spectrum of Myelin Oligodendrocytes Glycoprotein (MOG) antibody disease constitutes a recently described challenging entity, referring to a relatively new spectrum of autoimmune disorders with antibodies against MOG predominantly involving the optic nerve and spinal cord. The purpose of this article is to describe MRI features of MOG-AD involvement in the optic nerves, spinal cord and the brain of adults.


Demyelinating Diseases/diagnostic imaging , Demyelinating Diseases/pathology , Magnetic Resonance Imaging , Adolescent , Adult , Autoantibodies , Brain/diagnostic imaging , Brain/pathology , Demyelinating Diseases/immunology , Encephalitis/diagnostic imaging , Encephalitis/immunology , Encephalitis/pathology , Female , Humans , Male , Myelin-Oligodendrocyte Glycoprotein/immunology , Myelitis/diagnostic imaging , Myelitis/immunology , Myelitis/pathology , Optic Nerve/diagnostic imaging , Optic Nerve/pathology , Optic Neuritis/diagnostic imaging , Optic Neuritis/immunology , Optic Neuritis/pathology , Spinal Cord/diagnostic imaging , Spinal Cord/pathology , Young Adult
4.
Mult Scler Relat Disord ; 25: 216-218, 2018 Oct.
Article En | MEDLINE | ID: mdl-30114625

Unexpected high disease activity (UHDA) after Fingolimod withdrawal has recently become a controversial concern for physicians. Here, we report the case of a patient with severe exacerbation of MS after switching from Fingolimod to Alemtuzumab treatment. This UHDA despite profound lymphopenia raised the question of the management of sequential use of biotherapies such as Fingolimod and Alemtuzumab in MS.


Alemtuzumab/adverse effects , Antineoplastic Agents, Immunological/adverse effects , Drug Substitution/adverse effects , Fingolimod Hydrochloride/therapeutic use , Immunosuppressive Agents/therapeutic use , Multiple Sclerosis/drug therapy , Female , Humans , Magnetic Resonance Imaging , Middle Aged , Multiple Sclerosis/diagnostic imaging , Multiple Sclerosis/epidemiology
5.
J Alzheimers Dis ; 65(2): 443-453, 2018.
Article En | MEDLINE | ID: mdl-30056422

BACKGROUND: Anosognosia is a frequent symptom of Alzheimer's disease (AD), but its neural substrates remain in question. OBJECTIVE: In this study, we combined neuroimaging with a neuropsychological evaluation to assess neural substrates of anosognosia. METHODS: We prospectively recruited 30 patients with probable early-stage AD and matched healthy controls. Participants underwent MRI, FDG-PET, and a neuropsychological evaluation that includes an assessment of anosognosia. In the AD group, correlations between the anosognosia score, neuroimaging modalities, and neuropsychological performance were performed. RESULTS: Atrophy and hypometabolism were correlated with the anosognosia score in the left dorsal anterior cingulate cortex. The anosognosia score was also correlated with atrophy of the cerebellar vermis, the left postcentral gyrus, and the right fusiform gyrus. No relation was found between anosognosia and the neuropsychological assessment. DISCUSSION: Structural and metabolic alteration in the dorsal anterior cingulate cortex seems to be associated with a diminution of awareness in patients with early-stage AD.


Agnosia/diagnostic imaging , Agnosia/metabolism , Alzheimer Disease/diagnostic imaging , Alzheimer Disease/metabolism , Gyrus Cinguli/diagnostic imaging , Gyrus Cinguli/metabolism , Aged , Agnosia/psychology , Alzheimer Disease/psychology , Brain Mapping , Fluorodeoxyglucose F18 , Humans , Magnetic Resonance Imaging , Multimodal Imaging , Neuropsychological Tests , Positron-Emission Tomography , Radiopharmaceuticals
6.
J Alzheimers Dis ; 60(1): 253-262, 2017.
Article En | MEDLINE | ID: mdl-28826188

BACKGROUND: The relationship between cerebral microbleeds (CMB) and Alzheimer's disease (AD) has not yet been clearly determined, particularly with susceptibility weight-imaging (SWI). OBJECTIVE: To evaluate the SWI sequence using 3T MRI for the detection of CMB, and its ability to differentiate elderly control subjects (CS), stable mild cognitive impairment patients (MCI-s), MCI patients progressing to AD (MCI-p), and AD patients. METHODS: It was a prospective, monocentric, observational study that took place in Toulouse, France. Participants were 65 years and older, enrolled in three groups: CS, MCI, and AD. Based on the longitudinal analysis of cognitive decline, MCI subjects were retrospectively classified as MCI-s or MCI-p. Each patient had a 4-year follow-up with MRI at baseline (MRI#1) and during the fourth year (MRI#3). CMB were counted on native SWI images juxtaposed to minIP reformatted images. RESULTS: 150 patients were enrolled: 48 CS, 25 MCI-s, 18 MCI-p, 59 AD. At MRI#1 and at MRI#3, there was no significant difference in the prevalence of CMB between groups (p = 0.75 and p = 0.87). In the MCI-p + AD group, significantly more subjects had≥4 incident CMB compared to the CS + MCI-s group (p = 0.016). In the MCI-p + AD group, the prevalence of patients with >4 CMB was significantly higher at MRI#3 than at MRI#1 (p = 0.008). CONCLUSION: Using SWI, AD and MCI-p patients had developed significantly more new CMB than CS and MCI-s patients during the follow-up. Incident CMB might be suggested as a potential imaging marker of AD progression.


Cerebral Hemorrhage , Cognitive Dysfunction/complications , Magnetic Resonance Imaging , Aged , Aged, 80 and over , Alzheimer Disease/complications , Alzheimer Disease/etiology , Cerebral Hemorrhage/diagnostic imaging , Cerebral Hemorrhage/epidemiology , Cerebral Hemorrhage/etiology , Disease Progression , Female , Humans , Incidence , Longitudinal Studies , Male , Mental Status Schedule , Neuropsychological Tests
7.
BMC Neurol ; 16: 122, 2016 Jul 30.
Article En | MEDLINE | ID: mdl-27475058

BACKGROUND: Few patients are reported with dementia with Lewy bodies before fifty years-old, which may partly reflect the difficulty of accurate diagnosis in young population. We report the case of a 44-year-old male with pathologically confirmed sporadic dementia with Lewy bodies, who did not fulfil the revised clinical criteria for this disease. CASE PRESENTATION: We document this atypical case with clinical and cognitive evaluation, imaging, biochemistry, genetics and pathology investigations. Creutzfeldt-Jakob disease was first suspected in this patient with no previous medical history, who developed acute and rapid cognitive impairment, L-dopa-non-responsive parkinsonism, and delusion. Positive 14-3-3 protein was initially detected in cerebrospinal fluid and until the late stages of the disease. Severe atrophy with no diffusion hypersignal was found on structural MRI as well as an extensive hypometabolism on (18)F-FDG-PET, in comparison to age-matched healthy volunteers. Genetic investigation found no alpha-synuclein gene mutation. The patient died within 5 years, and post-mortem examination found numerous Lewy bodies and Lewy neurites consistent with pure Lewy body disease. CONCLUSIONS: This comprehensively described case illustrates that dementia with Lewy bodies can occur in young patients with atypical clinical presentation. Biochemistry and neuroimaging investigations can sometimes be insufficient to allow accurate diagnostic. More specific markers to support such diagnosis are needed.


Creutzfeldt-Jakob Syndrome/diagnosis , Lewy Body Disease/diagnosis , 14-3-3 Proteins/cerebrospinal fluid , Adult , Brain/pathology , Cognition Disorders/diagnosis , Creutzfeldt-Jakob Syndrome/diagnostic imaging , Creutzfeldt-Jakob Syndrome/pathology , Delusions/diagnosis , Diagnosis, Differential , Fatal Outcome , Fluorodeoxyglucose F18 , Follow-Up Studies , Humans , Lewy Body Disease/diagnostic imaging , Lewy Body Disease/pathology , Magnetic Resonance Imaging/methods , Male , Neuroimaging/methods , Parkinsonian Disorders/diagnosis , Positron-Emission Tomography/methods
10.
F1000Res ; 2: 283, 2013.
Article En | MEDLINE | ID: mdl-24715969

We report a case of simultaneous progressive multifocal leukoencephalopathy-associated immune reconstitution inflammatory syndrome (PML-IRIS) during corticosteroid tapering in a patient with an anti-synthetase syndrome. We describe the challenges associated with the diagnosis and the management of this emerging inflammatory neurological condition in this immunocompromised patient with a severe rheumatic disease. We highlight that, in the setting of IRIS, the low-level of the JC virus viral load requires a sensitive PCR assay before excluding PML.

12.
Clin Ther ; 30(2): 307-16, 2008 Feb.
Article En | MEDLINE | ID: mdl-18343269

BACKGROUND: The effectiveness of all prescribed treatments is contingent on patient adherence. The reported levels of adherence to recombinant human growth hormone (r-hGH) therapy are highly variable, but it has been suggested that nonadherence might be as high as 36% to 49%. OBJECTIVES: This commentary discusses the factors that affect long-term adherence to injection treatment, of which r-hGH therapy is a particular challenge. It also explores potential strategies to improve adherence to injection treatments in clinical practice. METHODS: The opinion of the authors was validated and supported by published literature. A PubMed literature search was conducted in November 2006, identifying English-language articles containing key terms growth hormone, adherence, and compliance. RESULTS: This study found that factors associated with poor adherence to injection treatments include patients' lack of understanding of their disease, patient age, chronicity of the disease, complex treatment regimens, and insufficient information on the implications of nonadherence. Strengthening the patient-physician relationship by providing the patient with a clear understanding of his/her disease and the benefits of adherence, making improvements in injection devices, and eliminating subjective illness concepts, might increase adherence to SC injection treatments, thereby reducing increasing health care costs associated with nonadherence. CONCLUSIONS: Poor adherence to r-hGH therapy has a dual effect, in that it leads to reduced efficacy out-comes and increased health care costs. Implementing strategies to improve adherence with injection treatment might be of particular clinical benefit to patients undergoing r-hGH therapy.


Hormone Replacement Therapy , Human Growth Hormone/therapeutic use , Medication Adherence , Age Factors , Chronic Disease , Comprehension , Health Care Costs , Health Knowledge, Attitudes, Practice , Hormone Replacement Therapy/economics , Human Growth Hormone/administration & dosage , Human Growth Hormone/economics , Humans , Injections, Subcutaneous , Patient Education as Topic , Physician-Patient Relations , Recombinant Proteins/therapeutic use
13.
BMC Endocr Disord ; 6: 5, 2006 Oct 11.
Article En | MEDLINE | ID: mdl-17034628

BACKGROUND: Recombinant human growth hormone (r-hGH) is used to treat: growth hormone deficiency in children and adults; children born small for gestational age; Turner's syndrome; and chronic renal failure. r-hGH is administered by daily subcutaneous injection and may be given using a number of different administration devices. The aim of this survey was, firstly, to identify which attributes of an r-hGH administration device are considered most important to physicians, teenage patients, parents of young children requiring GH and nurses who have experience of r-hGH administration, and, secondly, to determine how they rate existing devices in each of these key attributes. METHODS: The opinions of 67 individuals with experience in r-hGH administration were captured in discussion sessions. Parents, physicians and nurses were asked to rate 19 device attributes by completing a questionnaire, and to rank four different r-hGH administration devices (including a conceptual electronic device) in order of preference. RESULTS: Reliability, ease of use, lack of pain during injection, safety in use, storage, and number of steps in preparation before use, during use and after were considered to be the five most desirable attributes of an r-hGH administration device. An electronic device was preferred to an automatic, multi-dose injection device, a needle-free injection device or a manual, ready-to-use, disposable injection device. CONCLUSION: In the opinion of physicians, nurses and parents using r-hGH injection devices, an ideal device must combine reliability with simplicity, while delivering treatment with minimal pain. An electronic device, which combines many of the most useful features of existing devices with novel functions, was the preferred option for r-hGH administration.

14.
Prenat Diagn ; 23(2): 163-5, 2003 Feb.
Article En | MEDLINE | ID: mdl-12575026

The Jarcho-Levin syndrome is a specific form of spondylocostal/spondylothoracic dysostosis. There have been various classifications of this syndrome. We present the case of a severe prenatal Jarcho-Levin syndrome, diagnosed by ultrasound examination during the first trimester of pregnancy in a family with no previous medical history of an affected child. X-ray exploration, high-resolution spiral computed tomography and autopsy confirmed the diagnosis.


Abnormalities, Multiple/diagnostic imaging , Bone Diseases, Developmental/diagnostic imaging , Kidney Diseases/diagnostic imaging , Neck/abnormalities , Ribs/abnormalities , Spinal Dysraphism/diagnostic imaging , Abortion, Eugenic , Adult , Female , Humans , Kidney Diseases/congenital , Neck/embryology , Pregnancy , Pregnancy Trimester, First , Ribs/diagnostic imaging , Syndrome , Ultrasonography, Prenatal
...